MIMOSA Diagnostics
MIMOSA Diagnostics is a Canadian medical device company that develops and sells the FDA-cleared MIMOSA Pro, a handheld near-infrared multispectral imaging device that captures tissue oximetry, temperature, and wound measurements in under one second, serving hospitals, wound care clinics, and healthcare systems across the US and Canada via enterprise field sales plus a cloud subscription.
- Company typePrivate
- Founded2016
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MIMOSA Diagnostics does
MIMOSA Diagnostics is a Canadian medical device company, founded in 2016 and headquartered in Toronto with operations in Halifax, that develops and commercializes the MIMOSA Pro — a handheld, pocket-sized, non-contact near-infrared (NIR) reflectance-based multispectral imaging device that captures tissue oxygenation, temperature, wound measurement, and an HDR digital image in under one second. The underlying technology miniaturizes what were traditionally 12-foot hospital-grade imaging systems into a palm-sized point-of-care device, with images uploaded to a HIPAA-compliant cloud-based web portal for remote specialist review and longitudinal patient tracking. The device is US FDA 510(k) cleared and Health Canada approved, with established CPT reimbursement codes (0640T and 0859T) for non-contact near-infrared spectroscopy studies. Melanin-equivalent algorithms are in development to ensure equitable tissue assessment across all skin tones.
The company's revenue model is hybrid, combining hardware sales of the MIMOSA Pro device with an annual subscription for the cloud-based web portal, sold primarily through an enterprise field sales motion targeting hospitals, integrated delivery networks (IDNs), group practices, and specialized wound care clinics in the US and Canada. Secondary use cases extend into home health, post-operative flap monitoring, peripheral vascular disease, burns assessment, and pediatric low cardiac output syndrome detection — the latter through an ongoing 3-year clinical study developing predictive ML analytics. Distribution is direct enterprise sales supplemented by partnerships such as Venture Medical, with clinical validation anchored by a Hamilton Health Sciences pilot covering 3,500+ patient assessments and demonstrating 91% accuracy versus 40% for the standard Braden Scale in pressure injury detection.
The company is led by co-founders Dr. Karen Cross (CEO, surgeon) and Dr. General Leung (CTO, MRI physicist), with a commercial bench that includes President Nanci Gilmore (ex-SANUWAVE, THINK Surgical), CRO Jack Schlechtweg, COO Lilian Liao (ex-Swift Medical, BMO), VP Sales Brian Dowd (ex-J&J, FUJIFILM Healthcare, SANUWAVE), and Director Brian Greene (ex-Boston Scientific, Medtronic). The company has raised multiple funding rounds since 2016 from investors including Kern Venture Group, INOVAIT, BDC Venture Capital, MEDTEQ+, Creative Destruction Lab, FundersClub, and Pool Global Partners, and holds ISO 13485:2016 and SOC 2 Type 1 certifications.
MIMOSA Diagnostics firmographics
Firmographics- Name
- MIMOSA Diagnostics
- Legal name
- MIMOSA Diagnostics Inc.
- Website
- https://mimosadiagnostics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MIMOSA Diagnostics is a Canadian medical device company that develops and sells the FDA-cleared MIMOSA Pro, a handheld near-infrared multispectral imaging device that captures tissue oximetry, temperature, and wound measurements in under one second, serving hospitals, wound care clinics, and healthcare systems across the US and Canada via enterprise field sales plus a cloud subscription.
- Ownership category
- akta.pro rank
MIMOSA Diagnostics industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industry
- Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)
Keywords
Where MIMOSA Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
MIMOSA Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure
Revenue model
- MIMOSA Pro Device Sales: Sale of handheld tissue imaging hardware device to healthcare providers including hospitals, clinics, and practitioners
- Software/Web Portal Subscription: Cloud-based secure web portal for image storage, review, and collaboration. Reimbursement codes CPT 0640T and 0859T for near-infrared spectroscopy studies provide billing pathway
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Hybrid | Annual | Device plus cloud subscription with reimbursement pathway |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
MIMOSA Diagnostics product offering
Product offeringCore offering
MIMOSA Pro is a pocket-sized, handheld, non-contact near-infrared (NIR) multispectral imaging device that captures tissue oximetry, temperature, wound measurement, and an HDR digital image in under one second, paired with a secure cloud-based web portal for remote clinician review, patient physiology tracking, and reimbursement documentation. It is sold to hospitals, group practices, wound care clinics, home health agencies, and emergency/military medical settings in the US and Canada.
Product overview
MIMOSA Diagnostics offers a single unified product — the MIMOSA Pro handheld tissue imaging device — complemented by a cloud-based secure web portal for remote image review, patient tracking, and reimbursement documentation. The product portfolio consists of one core device (MIMOSA Pro) that functions as a pocket-sized multispectral NIR imaging system, paired with a companion app and cloud platform. MIMOSA Pro captures four simultaneous insights (tissue oximetry, temperature, wound measurement, and HDR digital image) in under one second at the point-of-care, with images relayed to the web portal for remote specialist analysis and longitudinal patient monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- MIMOSA Pro: Handheld near-infrared tissue oximetry imaging device for wound care assessment
- MIMOSA Pro Portal
Products and services
- MIMOSA Pro Handheld Imaging Device MIMOSA Pro is a pocket-sized, handheld, non-contact near-infrared (NIR) reflectance-based multispectral imaging device that captures tissue oximetry, temperature, wound measurement, and an HDR digital image in under one second without patient contact. It is sold to healthcare providers including hospitals, group practices, specialized wound care clinics, home health agencies, and emergency/military settings in the US and Canada. The device is US FDA 510(k) cleared and Health Canada approved.
- MIMOSA Pro Portal (Cloud-Based Web Portal) Secure HIPAA-compliant and SOC 2 Type 1 certified cloud-based web portal that stores multispectral tissue images captured by MIMOSA Pro, enables remote specialist review, tracks patient physiology over time, and supports reimbursement documentation for healthcare providers.
Quantifiable outcome
- MIMOSA Pro correctly identified absence of early pressure injury signs 91% of the time compared to 40% using standard Braden Scale assessment method
- +2 more outcomes
Companies that use MIMOSA Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
MIMOSA Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
MIMOSA Diagnostics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Hamilton Health SciencescoreFour-month pilot study conducted across multiple HHS hospitals (Juravinski Hospital, McMaster Children's Hospital) involving over 3,500 patient assessments. HHS continuing research in partnership with MIMOSA Diagnostics and CAN Health Network to determine device effectiveness across skin tones.
- CAN Health NetworkcorePartnership with CAN Health Network for clinical validation and research collaboration on MIMOSA Pro technology for early detection applications.
- Nova Scotia Health Innovation HubcoreHealth Innovation Hub partner with game-changing wound care technology. MIMOSA Pro received Health Canada approval through this partnership support.
- Ontario Centre of InnovationminorFeatured as success story for MIMOSA Diagnostics' portable imaging device saving limbs and lives.
- Venture MedicalminorPartnership announced for distribution and commercialization of MIMOSA technology.
- Henson ShavingminorMIMOSA Labs inked deal with Henson Shaving as first clinical research partner.
Scale indicators5 records
Recent moves8 records
Expansion highlights7 records
MIMOSA Diagnostics competitors and assessment
Company assessmentDirect peers
- MolecuLight: Handheld fluorescence-based wound imaging device for bacterial detection and wound measurement. Directly competes with MIMOSA Pro in the point-of-care wound imaging category serving wound care clinicians and hospitals.
- Kent Imaging: Manufacturer of SnapshotNIR, a near-infrared spectroscopy (NIRS) tissue oximetry imaging device for wound and perfusion assessment. Closest direct competitor to MIMOSA Pro given overlapping NIRS technology and clinical indications.
- HyperMed Imaging: Provider of hyperspectral imaging solutions for tissue oxygenation and perfusion assessment in clinical and research settings. Competes in the same NIR/spectral tissue oximetry category as MIMOSA Pro.
- Swift Medical: Digital wound care management platform with AI-powered wound imaging. Competes in wound assessment workflows; MIMOSA's COO Lilian Liao previously served as VP Operations at Swift Medical, highlighting the adjacency.
- Spectral MD: Developer of DeepView, a multispectral imaging system for wound healing assessment and burn depth evaluation. Overlaps with MIMOSA's wound care, burns, and diabetic foot use cases.
Emerging players
- Tissue Analytics: AI-powered wound imaging and analytics platform (acquired by Net Health). Competes in digital wound documentation and tissue assessment workflows, partially overlapping with MIMOSA's portal offering.
- Bruker BioSpin: Provides preclinical and clinical MRI/NIR imaging systems including preclinical tissue oxygenation measurement. Adjacent technology provider relevant to NIR spectroscopy-based tissue assessment.
Broad incumbents
- Smith+Nephew: Global medical device company with a major Advanced Wound Management portfolio. Provides broader wound care solutions that may include or integrate imaging as part of larger wound care pathways.
- Mölnlycke Health Care: Global wound care and surgical solutions company with established hospital sales channels. Represents a potential channel partner or competitive incumbent for advanced wound care imaging solutions.
Regional players
- Sanuwave: Medical device company focused on acoustic pressure wave and wound care technologies. MIMOSA's President and VP Sales both come from Sanuwave, indicating direct category knowledge of this competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
MIMOSA Diagnostics social profiles
Digital presenceMIMOSA Diagnostics compliance and trust
Trust signalCompliance3 records
MIMOSA Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MIMOSA Diagnostics leadership team
Management profileNumber of profiles
Profiles15 records
MIMOSA Diagnostics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MIMOSA Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MIMOSA Diagnostics
What does MIMOSA Diagnostics do?
MIMOSA Pro is a pocket-sized, handheld, non-contact near-infrared (NIR) multispectral imaging device that captures tissue oximetry, temperature, wound measurement, and an HDR digital image in under one second, paired with a secure cloud-based web portal for remote clinician review, patient physiology tracking, and reimbursement documentation. It is sold to hospitals, group practices, wound care clinics, home health agencies, and emergency/military medical settings in the US and Canada.
Is MIMOSA Diagnostics a public or private company?
MIMOSA Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was MIMOSA Diagnostics founded?
MIMOSA Diagnostics was founded in 2016. It employs 11 to 50 people.
Where is MIMOSA Diagnostics based?
MIMOSA Diagnostics is headquartered in Toronto, Canada, in the North America region.
How does MIMOSA Diagnostics make money?
Two revenue lines are on record. MIMOSA Pro Device Sales are the primary driver. The others are software/Web Portal Subscription.
Who are MIMOSA Diagnostics's main competitors?
Direct peers on record are MolecuLight, Kent Imaging, HyperMed Imaging, Swift Medical and Spectral MD. Emerging players are Tissue Analytics and Bruker BioSpin. Broad incumbents are Smith+Nephew and Mölnlycke Health Care. Sanuwave is listed as a regional player.
Does MIMOSA Diagnostics have an API?
No public API is recorded for MIMOSA Diagnostics.
What industry is MIMOSA Diagnostics in?
MIMOSA Diagnostics's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334510 and its SIC code is 3845.